Home/Filings/4/0001415889-21-001896
4//SEC Filing

PAREKH RAJESH B 4

Accession 0001415889-21-001896

CIK 0001035354other

Filed

Apr 4, 8:00 PM ET

Accepted

Apr 5, 8:33 PM ET

Size

10.2 KB

Accession

0001415889-21-001896

Insider Transaction Report

Form 4
Period: 2021-04-01
Transactions
  • Award

    Common Stock

    2021-04-01+2,445,2392,445,239 total(indirect: See footnote)
  • Award

    Common Stock

    2021-04-01+87,03187,031 total(indirect: See footnote)
  • Award

    Stock Option (Right to Buy)

    2021-04-01+40,00040,000 total
    Exercise: $3.36Exp: 2031-04-01Common Stock (40,000 underlying)
Footnotes (5)
  • [F1]Received by Advent Life Sciences LLP in exchange for 345,785 Series A Preferred and 1,321,888 Series A-1 Preferred shares of Zikani Therapeutics, Inc. ("Zikani") in connection with the acquisition of Zikani by the Issuer.
  • [F2]Held directly by Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein.
  • [F3]Received by Advent Life Sciences Fund II LLP in exchange for 9,715,135 Series A Preferred and 37,139,650 Series A-1 Preferred shares of Zikani in connection with the acquisition of Zikani by the Issuer.
  • [F4]Held directly by Advent Life Sciences Fund II LLP. Advent Life Sciences LLP is the manager of Advent Life Sciences Fund II LLP and the Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein.
  • [F5]The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one-half (1/2) of the shares underlying the option shall vest on April 1, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

Issuer

Eloxx Pharmaceuticals, Inc.

CIK 0001035354

Entity typeother

Related Parties

1
  • filerCIK 0001429930

Filing Metadata

Form type
4
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 8:33 PM ET
Size
10.2 KB